What is Zacks Research’s Forecast for BMY FY2026 Earnings?

Bristol Myers Squibb Company (NYSE:BMY) – Equities research analysts at Zacks Research boosted their FY2026 earnings per share (EPS) estimates for Bristol Myers Squibb in a research note issued on Friday, September 11th. Zacks Research analyst Team now expects that the biopharmaceutical company will earn $6.86 per share for the year, up from their previous estimate of $6.85. The consensus estimate for Bristol Myers Squibb’s current full-year earnings is $6.95 per share. Zacks Research also issued estimates for Bristol Myers Squibb’s Q4 2026 earnings at $1.65 EPS, Q2 2027 earnings at $1.74 EPS, Q4 2027 earnings at $1.53 EPS, FY2027 earnings at $6.23 EPS, Q1 2028 earnings at $1.47 EPS, Q2 2028 earnings at $1.37 EPS and FY2028 earnings at $5.17 EPS.

Several other research analysts also recently commented on the stock. Argus raised shares of Bristol Myers Squibb from a “hold” rating to a “buy” rating and set a $75.00 price objective for the company in a report on Wednesday, August 5th. Truist Financial reissued a “buy” rating and set a $70.00 target price (up from $65.00) on shares of Bristol Myers Squibb in a report on Friday, July 31st. Roth Capital began coverage on Bristol Myers Squibb in a research report on Wednesday, August 5th. They set a “buy” rating and a $75.00 target price on the stock. Piper Sandler assumed coverage on Bristol Myers Squibb in a research report on Wednesday, August 5th. They issued an “overweight” rating for the company. Finally, Royal Bank Of Canada boosted their price objective on Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “sector perform” rating in a research note on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $66.33.

Bristol Myers Squibb Price Performance

BMY opened at $64.08 on Monday. The firm has a 50-day moving average price of $63.76 and a 200-day moving average price of $60.08. Bristol Myers Squibb has a twelve month low of $42.52 and a twelve month high of $68.64. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89. The company has a market capitalization of $130.90 billion, a price-to-earnings ratio of 14.12, a PEG ratio of 0.30 and a beta of 0.23.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.60 by $0.44. The business had revenue of $12.97 billion during the quarter, compared to analyst estimates of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.Bristol Myers Squibb’s revenue was up 5.7% compared to the same quarter last year. During the same period in the prior year, the company earned $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS.

Institutional Investors Weigh In On Bristol Myers Squibb

Institutional investors and hedge funds have recently bought and sold shares of the stock. California State Teachers Retirement System grew its stake in shares of Bristol Myers Squibb by 5,484.7% during the second quarter. California State Teachers Retirement System now owns 185,255,963 shares of the biopharmaceutical company’s stock valued at $10,674,449,000 after buying an additional 181,938,762 shares during the last quarter. Norges Bank bought a new stake in shares of Bristol Myers Squibb during the 4th quarter worth approximately $1,947,272,000. Primecap Management Co. CA purchased a new position in Bristol Myers Squibb during the 2nd quarter valued at $1,436,115,000. Legal & General Group Plc purchased a new position in Bristol Myers Squibb during the 2nd quarter valued at $980,862,000. Finally, BlackRock Inc. grew its position in Bristol Myers Squibb by 5.1% in the 2nd quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock valued at $10,393,783,000 after acquiring an additional 8,702,106 shares during the last quarter. 76.41% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, SVP Phil M. Holzer sold 500 shares of the business’s stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total transaction of $33,750.00. Following the completion of the transaction, the senior vice president owned 16,862 shares of the company’s stock, valued at approximately $1,138,185. The trade was a 2.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.05% of the company’s stock.

Bristol Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd were issued a $0.63 dividend. The ex-dividend date of this dividend was Thursday, July 2nd. This represents a $2.52 annualized dividend and a dividend yield of 3.9%. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 55.51%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its portfolio includes therapies for cancer, blood disorders, cardiovascular disease, immune-mediated conditions and psychiatric disorders. Key products include Opdivo and Yervoy for oncology, Eliquis for reducing the risk of stroke and systemic embolism, Revlimid for certain blood cancers, and several other specialty medicines.

The company serves patients and healthcare providers in markets around the world, with operations and commercial activities spanning North America, Europe, Asia-Pacific and other international regions.